However, SRC is overexpressed in various solid tumors, including breast, pancreatic, gastric, and bladder cancers, where it accelerates tumor cell growth and survival (Luo et al., 2022; Su et al., 2023; Wang et al., 2022; Xu et al., 2021). Here, SRC is linked to urinary bladder cancer.